dipyridamole has been researched along with Germinoblastoma in 14 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was purposed to explore the expressions of platelet-activated markers PAC-1 and CD62p in peripheral blood of malignant lymphoma patients and the influence of dipyridamole on their expression." | 9.14 | [Influence of dipyridamole on expression of PAC-1 and CD62p in patients with malignant lymphoma]. ( Jiang, YJ; Kang, LL; Li, XM; Wang, HX; Zhu, GH; Zhuang, WC, 2010) |
| "The availability of a human lymphoma cell line deficient in adenosine deaminase, adenosine kinase and methylthioadenosine phosphorylase enabled us to compare the effects of nucleoside transport inhibitors on the excretion of endogenously generated adenosine, deoxyadenosine and 5'-methylthioadenosine." | 7.67 | Modulation of adenine nucleoside excretion and incorporation in adenosine deaminase deficient human lymphoma cells. ( Carson, DA; Iizasa, T; Kubota, M, 1984) |
| "This study was purposed to explore the expressions of platelet-activated markers PAC-1 and CD62p in peripheral blood of malignant lymphoma patients and the influence of dipyridamole on their expression." | 5.14 | [Influence of dipyridamole on expression of PAC-1 and CD62p in patients with malignant lymphoma]. ( Jiang, YJ; Kang, LL; Li, XM; Wang, HX; Zhu, GH; Zhuang, WC, 2010) |
| "In an attempt to identify the target protein, P-GP or mrp, of each MDR antagonist, verapamyl (Ver), dipyridamole (Dip), or cyclosporin A (Cy-A), this study was designed to compare the activity of the three afore-mentioned drugs and to test their combined effect on the cidal activity of vincristine (VCR) in five types of wild and the corresponding VCR-resistant cultured cell lines from human leukemia and lymphoma." | 3.70 | Effect of MDR antagonists on the cidal activity of vincristine for cells expressing MDR-1 is superior to those expressing MRP. ( Hamano, S; Hirose, M; Hosoi, E; Kuroda, Y; Morimoto, M, 1998) |
| "S49 murine lymphoma cells were examined for expression of various nucleoside transport systems using a non-metabolized nucleoside, formycin B, as substrate." | 3.68 | Na(+)-dependent, active nucleoside transport in S49 mouse lymphoma cells and loss in AE-1 mutant deficient in facilitated nucleoside transport. ( Plagemann, PG, 1991) |
| "The availability of a human lymphoma cell line deficient in adenosine deaminase, adenosine kinase and methylthioadenosine phosphorylase enabled us to compare the effects of nucleoside transport inhibitors on the excretion of endogenously generated adenosine, deoxyadenosine and 5'-methylthioadenosine." | 3.67 | Modulation of adenine nucleoside excretion and incorporation in adenosine deaminase deficient human lymphoma cells. ( Carson, DA; Iizasa, T; Kubota, M, 1984) |
| "Plasma membrane-enriched fractions from disrupted S49 lymphoma cells contained high affinity sites for [3H]nitrobenzylthioinosine, a potent and specific inhibitor of nucleoside transport." | 3.67 | Identification of the nucleoside transporter in cultured mouse lymphoma cells. Photoaffinity labeling of plasma membrane-enriched fractions from nucleoside transport-competent (S49) and nucleoside transport-deficient (AE1) cells with [3H]nitrobenzylthioin ( Belt, JA; Gati, WP; Jarvis, SM; Paterson, AR; Young, JD, 1984) |
| "Dipyridamole use was related to a lower risk of lymphoid neoplasms, indicating a clinical potential of dipyridamole to be an adjunct anti-tumour agent against lymphoid neoplasms." | 1.72 | Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study. ( Huang, W; Ji, J; Sundquist, J; Sundquist, K, 2022) |
| "Two cases of Toxic Epidermal Necrolysis, with a previous history of drugs intake, and associated to a lymphoma and to a chronic lymphoid leukemia, are presented." | 1.29 | [Toxic epidermal necrolysis associated with lymphoproliferative syndromes. Anatomo-clinical study. Presentation of 2 cases]. ( Aguado Santos, A; Gomez Duaso, AJ; Ortiz Reina, S; Sanz Asenjo, A; Seoane Leston, JM, 1993) |
| "Dipyridamole could prove to be a useful drug for reversing the drug resistance caused by the activation of the salvage pathway." | 1.29 | Mechanism of the discrepant effect of a combination of methotrexate plus dipyridamole on human hematologic cell lines. ( Hirose, M; Kuroda, Y; Takeda, E, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (57.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, W | 1 |
| Sundquist, K | 1 |
| Sundquist, J | 1 |
| Ji, J | 1 |
| Jiang, YJ | 1 |
| Li, XM | 1 |
| Wang, HX | 1 |
| Kang, LL | 1 |
| Zhu, GH | 1 |
| Zhuang, WC | 1 |
| Iizasa, T | 1 |
| Kubota, M | 1 |
| Carson, DA | 1 |
| Young, JD | 1 |
| Jarvis, SM | 1 |
| Belt, JA | 2 |
| Gati, WP | 1 |
| Paterson, AR | 1 |
| Seoane Leston, JM | 1 |
| Gomez Duaso, AJ | 1 |
| Sanz Asenjo, A | 1 |
| Ortiz Reina, S | 1 |
| Aguado Santos, A | 1 |
| Hirose, M | 3 |
| Takeda, E | 2 |
| Kuroda, Y | 3 |
| Hosoi, E | 1 |
| Hamano, S | 1 |
| Morimoto, M | 1 |
| Plagemann, PG | 2 |
| Beck, J | 1 |
| Ullman, B | 2 |
| Noel, LD | 1 |
| Ninomiya, T | 1 |
| Miyao, M | 1 |
| Aronow, B | 1 |
| Toll, D | 1 |
| Patrick, J | 1 |
| McCartan, K | 1 |
| Parks, RE | 1 |
| Dawicki, DD | 1 |
| Agarwal, KC | 1 |
| Chen, SF | 1 |
| Stoeckler, JD | 1 |
| Wohlhueter, RM | 1 |
1 trial available for dipyridamole and Germinoblastoma
| Article | Year |
|---|---|
[Influence of dipyridamole on expression of PAC-1 and CD62p in patients with malignant lymphoma].
Topics: Adolescent; Adult; Aged; Dipyridamole; Dual Specificity Phosphatase 2; Female; Fibrinogen; Humans; L | 2010 |
13 other studies available for dipyridamole and Germinoblastoma
| Article | Year |
|---|---|
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Chemoprevention; Comorbidity; Dipyridamole; Disease Susceptibility | 2022 |
Modulation of adenine nucleoside excretion and incorporation in adenosine deaminase deficient human lymphoma cells.
Topics: Adenosine; Adenosine Deaminase; Adenosine Kinase; Biological Transport; Cell Division; Cell Line; De | 1984 |
Identification of the nucleoside transporter in cultured mouse lymphoma cells. Photoaffinity labeling of plasma membrane-enriched fractions from nucleoside transport-competent (S49) and nucleoside transport-deficient (AE1) cells with [3H]nitrobenzylthioin
Topics: Adenosine; Affinity Labels; Animals; Binding, Competitive; Blood Proteins; Cell Line; Cell Membrane; | 1984 |
[Toxic epidermal necrolysis associated with lymphoproliferative syndromes. Anatomo-clinical study. Presentation of 2 cases].
Topics: Anesthetics; Dipyridamole; Fatal Outcome; Female; Humans; Insulin; Leukemia, Lymphocytic, Chronic, B | 1993 |
Mechanism of the discrepant effect of a combination of methotrexate plus dipyridamole on human hematologic cell lines.
Topics: Adult; Cell Division; Child; Dipyridamole; Drug Resistance; Drug Screening Assays, Antitumor; Drug S | 1993 |
Effect of MDR antagonists on the cidal activity of vincristine for cells expressing MDR-1 is superior to those expressing MRP.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Bind | 1998 |
Na(+)-dependent, active nucleoside transport in S49 mouse lymphoma cells and loss in AE-1 mutant deficient in facilitated nucleoside transport.
Topics: Aminoisobutyric Acids; Animals; Biological Transport, Active; Carrier Proteins; Dipyridamole; Formyc | 1991 |
Expression of a novel high affinity purine base transport system in mutant mouse S49 cells does not require a functional nucleoside transporter.
Topics: Adenine; Animals; Biological Transport; Clone Cells; Dipyridamole; Dose-Response Relationship, Drug; | 1989 |
Nucleoside transport in Walker 256 rat carcinosarcoma and S49 mouse lymphoma cells. Differences in sensitivity to nitrobenzylthioinosine and thiol reagents.
Topics: 4-Chloromercuribenzenesulfonate; Animals; Biological Transport; Carcinoma 256, Walker; Cell Line; Di | 1985 |
Inhibitory effect of dipyridamole on the growth of various human hematologic malignant cell lines.
Topics: Adolescent; Adult; Child; Child, Preschool; Dipyridamole; DNA, Neoplasm; Female; Humans; Infant; Inf | 1986 |
Dipyridamole-insensitive nucleoside transport in mutant murine T lymphoma cells.
Topics: Animals; Biological Transport; Cell Line; Dipyridamole; Kinetics; Lymphoma; Mice; Mutation; Purine N | 1986 |
Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Azepines; Biological Transport, Active; Cell Li | 1985 |
S49 mouse lymphoma cells are deficient in hypoxanthine transport.
Topics: Adenine; Animals; Biological Transport; Cell Line; Cricetinae; Cricetulus; Dipyridamole; Hypoxanthin | 1986 |